Efavirenz Treatment and False‐Positive Results in Benzodiazepine Screening Tests | Zendy

Antje Blank | Zendy; Victoria Hellstern | Zendy; D. Schuster | Zendy; Martin Hartmann | Zendy; A. Matthee | Zendy; Jürgen Burhenne | Zendy; Walter E. Haefeli | Zendy; Gerd Mikus | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efavirenz Treatment and False‐Positive Results in Benzodiazepine Screening Tests

Author(s) -

Antje Blank,

Victoria Hellstern,

D. Schuster,

Martin Hartmann,

A. Matthee,

Jürgen Burhenne,

Walter E. Haefeli,

Gerd Mikus

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/599109

Subject(s) - efavirenz , medicine , drug , urine , benzodiazepine , pharmacology , pharmacokinetics , metabolite , sida , gastroenterology , human immunodeficiency virus (hiv) , virology , viral disease , antiretroviral therapy , viral load , receptor

We investigated the effect of efavirenz treatment on the results of drug screening tests of urine samples obtained from 100 patients infected with human immunodeficiency virus. Of 50 patients who received efavirenz, 49 tested positive for benzodiazepines in > or =1 drug screening test, whereas of 50 patients who did not receive efavirenz, only 1 tested positive for benzodiazepines in > or =1 drug screening test. The major metabolite 8-hydroxy-efavirenz is responsible for this cross-reactivity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research